Prestige Consumer Healthcare (PBH) Total Non-Current Liabilities (2013 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Total Non-Current Liabilities came in at $1.7 billion in Q4 2025, up 8.04% year-on-year from $1.5 billion in Q4 2024, and up 2.95% quarter-over-quarter from $1.6 billion in Q3 2025.
Prestige Consumer Healthcare (PBH) Total Non-Current Liabilities (2013 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $1.7 billion for Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 8.04% year-over-year to $1.7 billion in Q4 2025; TTM through Dec 2025 was $1.7 billion, a 8.04% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, down 5.57% from the prior year.
- Total Non-Current Liabilities improved to $1.7 billion in Q4 2025 per PBH's latest filing, from $1.6 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.2 billion in Q3 2021 and bottomed at $1.5 billion in Q4 2024.
- The 5-year median for Total Non-Current Liabilities is $1.8 billion (2023), against an average of $1.8 billion.
- Across the five-year window, Total Non-Current Liabilities retreated 15.76% in 2023 and climbed 8.04% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $2.1 billion in 2021, then slipped by 3.69% to $2.1 billion in 2022, then slipped by 15.76% to $1.7 billion in 2023, then dropped by 11.23% to $1.5 billion in 2024, then rose by 8.04% to $1.7 billion in 2025.
- Per Business Quant, the three latest PBH Total Non-Current Liabilities figures stand at $1.7 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.6 billion (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 1.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.66 Bn |
| Sep 30, 2025 | 1.61 Bn |
| Jun 30, 2025 | 1.57 Bn |
| Mar 31, 2025 | 1.56 Bn |
| Dec 31, 2024 | 1.54 Bn |
| Sep 30, 2024 | 1.58 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | 1.65 Bn |
| Dec 31, 2023 | 1.73 Bn |
| Sep 30, 2023 | 1.79 Bn |
| Jun 30, 2023 | 1.86 Bn |
| Mar 31, 2023 | 1.90 Bn |
| Dec 31, 2022 | 2.05 Bn |
| Sep 30, 2022 | 2.05 Bn |
| Jun 30, 2022 | 2.09 Bn |
| Mar 31, 2022 | 2.09 Bn |
| Dec 31, 2021 | 2.13 Bn |
| Sep 30, 2021 | 2.21 Bn |
| Jun 30, 2021 | 2.13 Bn |
| Mar 31, 2021 | 2.06 Bn |